Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by qwerty22on Apr 26, 2021 4:26pm
115 Views
Post# 33068721

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:TH's website issues

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:TH's website issues

Yeah that's true, the analyst situation has got worse and worse rather than improving, that needs a fix but I guess my point is I don't think it's the cause of the situation. The horrible thing is SPCEO identified that this was a company in transition back in early 2019, it was a great observation to make so early, it seems like it's still ongoing. I don't know if that's unacceptable or not, they are executing on that transition just not on a timetable that's pleasing to us legacy investors. The burden of missing out for the last 3 years is huge.


juniper88 wrote: The problem isn't simply the current market cap of THTX.  The fact that there were no questions asked at the last CC doesn't set off some red flags?  No fixing needed there?

 

qwerty22 wrote:

Sutro is also a good example of the evolution of these stocks. Prior to mid-202 the stock was around THTX's present market cap. It was having occasional stronger vol days but most of the time it was sub 100,000 shares traded. It had it's preclinical data and earliest clinical observations. You could have easily thought it was a stock with huge potential, ignored, badly marketed. It's SP and vol took off on the back of more solid data and commercial advancement. I don't believe what they did was suddenly improve their marketing I think they delivered commercially. Why can't we be just in the same position Sutro was in 12 months ago? With the potential to build from what looks superficially as a very similar base.

The only thing I'm ignoring here is NASH, NASH is the only thing not fitting this picture. As hard as it is to say given how long we have been waiting for this but I think this bullboard is just way ahead of everybody in their expectations around NASH. Dial it back (not all the way to zero) and the problems look less in need of urgent fixing. I'm not against getting insight into their strategies.

 

qwerty22 wrote:

 

So you expect nothing new? Maybe reassuring words?

I don't expect they reveal their capital market strategy, who they have engaged with, what the feedback was, when they expect to see results etc etc. I don't expect anything of substance or any admittance of failure. I don't expect them to commit to do certain specific things in the future or give guidance of when their present strat might begin to bear fruit or how or when they will change their present strat if it doesn't work.

As Wino says I expect the best will be a shared frustration in the present situation.

I think if the company commited to some type of public statement that might give them the space to say something new.

Letter from the CEO

Beloved Shareholders,

...

 

palinc2000 wrote: Of course Wino wont be privy to any material information  not yet in the public domain whether or not he reports he goes public,

 

 

qwerty22 wrote:

You will be going public here though? Don't you think that's going to limit what they say? If this is a productive process you should encourage the company to put out a statement. Letter to shareholders from the CEO type announcement.

 

Wino115 wrote: Wasn't planning on any written stuff agreed upon with them. This shouldn't be confrontational and I certainly don't want that. Like I said, I will bet my bottom  dollar on it they are equally frustrated and agree we are working toward the exact same goal. We just have a view on who we should draft for the team to win the cup.
 

 

SPCEO1 wrote: I agree. Let's just let Wino handle this however he thinks best.
palinc2000 wrote:

I dont think having them agree to a wrtten summary of the meeting is s good idea ....
Creating a sense of legal liability is not the way to have an open , frank discussion ... on the contrary !

 

scarlet1967 wrote:

 

I am not overly optimistic but since you have made the effort I would like to point out few things although you probably know:
1-You are not as good as they you are BETTER.
2-It seems you have already prepared your pitch with few requests, don’t let them bargain it is NOT a negotiation.
3-You can elaborate on your requests but most of the conversation should be about their responses.
4-Stay on topics don’t let them distract you from the purpose of the meeting.
5-If they can’t present solid plans to address the issues schedule another meeting as soon as possible so the company can respond with concrete solutions.
6-Leave the door open for future conversations so the company can interact with the shareholders on an ongoing basis.
5-Ideally everything should be in writing but since this is an informal meeting it would be a good idea if you could draft a summary of the meeting and email it back to the company for their review/approval before reporting back to the investors so there is an element of liability to the whole exercise.
 

Wino115 wrote: The only person I contacted was Paul.  Although, I have noticed a ton of people with familiar names pinged my LinkedIn.

Bucknelly21 wrote:
 
great who contacted you wino?
 

 

 

 

 

 

 

 

 

 




<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse